Glioblastoma (GBM) Treatment - Optune® Official Patient Site May 9, 2022, 5:46 a.m.
Optune is a wearable, portable, FDA-approved treatment for glioblastoma (GBM) that works by creating Tumor Treating Fields (TTFields), which are electric fields that disrupt cancer cell division.
A Closer Look at Glioblastoma and New Reasons for Hope April 22, 2022, 2:48 p.m.
Approximately 15,000 Americans will be diagnosed with glioblastoma this year. Although considered a rare cancer, doctors are seeing an increase in cases of the aggressive and deadly brain cancer that’s notoriously hard to treat. A local organization that’s helping enroll brain cancer patients in clinical trials around the world gives signs of hope.
Kazia Therapeutics completes phase II trial of paxalisib in glioblastoma April 22, 2022, 2:47 p.m.
The phase II study is now complete, and Kazia has the report, with chief executive officer Dr James Garner saying the company was looking forward to sharing the detailed data with clinicians and investors over coming months.
Qué es el glioblastoma: síntomas y tratamiento de un tumor cerebral agresivo April 20, 2022, 4:20 p.m.
El glioblastoma es el tumor cerebral primario más frecuente y de peor pronóstico. Tiene una evolución rápida y su aparición puede provocar cefaleas, somnolencia, convulsiones y problemas neurológicos que afecten a la visión, al habla y al movimiento.
UF to test novel CAR-modified T-cell technique in clinical trial for glioblastoma April 20, 2022, 4:20 p.m.
The trial builds upon preclinical research by Huang and team that demonstrated a novel technique using the injection ofgenetically modified cells to enhance the effectiveness of a form of immunotherapy known as chimeric antigen receptor therapy, or CAR T-cell therapy, in targeting glioblastoma. Using treatment-resistant tumor models in cells and mice, the team showed that using modified cells may reverse immunosuppression triggered by a tumor, thus enhancing the effectiveness of therapy to halt or even shrink tumor growth and potentially yield long-term protection.
Phantosmia and dysgeusia as the first presentation of glioblastoma April 20, 2022, 4:19 p.m.
Glioblastoma is a stage IV rapidly progressive glioma. Patients typically present with subacute, progressive focal neurological symptoms relative to the tumor location. Focal neurological deficits are more likely than seizures to be the presenting symptom of glioblastoma. Any neurological deficit necessitates diagnostic imaging to rule out organic causes such as infection, neoplasm, or vascular abnormalities that can mimic symptoms seen with glioblastoma. Herein we report a case of glioblastoma presenting with new onset symptoms of seizure auras without a prior history or other focal neurological symptoms.
Most deadly form of brain cancer that kills more than half of patients within a year April 18, 2022, 7:30 a.m.
Brain cancer is rare, being detected in about one in 15,000 Americans every year official figures show. But at a high school in New Jersey more than 100 students have been found to have the condition.
Emerging therapies for glioblastoma: current state and future directions April 18, 2022, 7:29 a.m.
Immunotherapy including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have offered new hope for improving GBM outcomes; ongoing studies are using combinatorial therapies with the aim of minimizing adverse side-effects and augmenting antitumor immune responses. In addition, techniques to overcome the blood-brain barrier (BBB) for targeted delivery are being tested in clinical trials in patients with recurrent GBM.
New CAR T-cell therapy for solid tumors was safe and showed early efficacy – April 11, 2022, 7:56 a.m.
A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.
Novel therapy advances to clinical trial for the treatment of glioblastoma April 11, 2022, 6:46 a.m.
The treatment evolved from years of research led by Christopher Chitambar, MD, and his lab to study iron-dependent processes in cancer biology and the mechanisms by which gallium compounds target iron metabolism and block malignant cell growth. In preclinical studies, Drs. Chitambar and Kathleen Schmainda, PhD, discovered that when administered intravenously, gallium maltolate (GaM) significantly slowed the growth of glioblastoma in a rat brain tumor model. Additional studies showed that GaM, administered orally to glioblastoma-bearing rats, significantly reduced the size of their tumors and prolonged survival.
Overcoming the BBB April 10, 2022, 6:24 p.m.
There has been growing interest in the development of exosomes as vehicles to deliver therapeutic substances to brain tissues and alter CNS functions. Being natural delivery vehicles for genetic material, several proof-of-concept studies have concluded that exosomes derived from the CNS and circulating in the blood have a BBB permeability similar to liposomes. But unlike liposomes, they accumulate in endothelial cells. Ultimately, the fulfillment of exosomal therapy may hinge on the development of suitable strategies for exosome production, characterization, targeting, and loading.
Glioblastoma (grade IV) April 4, 2022, 5:29 a.m.
Normally, astrocytes are responsible for a variety of roles, including providing nutrients to neurons, maintaining the blood-brain barrier, and modulating neurotransmission (how neurons communicate with each other). Glioblastomas often develop in the cerebral hemispheres of the brain, but may occur in almost any area of the brain or spinal cord. They are especially malignant, given that the tumor cells proliferate quickly, and are supported by an extensive network of blood vessels.
Nou tractament per eliminar el càncer més agressiu del cervell, el glioblastoma March 28, 2022, 1:32 p.m.
Després de dues dècades sense avenços en el tractament del glioblastoma, aquesta nova investigació obre una porta a l'esperança per tractar el glioblastoma, que suposa el 40% de tumors de cervell.
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments Feb. 28, 2022, 9:31 a.m.
The latest advances have been the use of GBM organoids or 3D-bioprinted mini-brains. 3D bio-printing mimics tissue cytoarchitecture by combining different types of cells interacting with each other and with extracellular matrix components. These in vivo models faithfully replicate human diseases in which the effect of new drugs can easily be tested.
A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion Feb. 14, 2022, 3:19 p.m.
Using in vitro and ex vivo models of GBM, we found that F114 inhibits GBM proliferation and invasion. These results establish F114 as a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future drug development efforts for GBM, and potentially other cancers.
Prognostic and Predictive Factors in Elderly Patients With Glioblastoma Feb. 14, 2022, 3:17 p.m.
The findings of this study have suggested that, on the premise of protecting function as much as possible, the more aggressive treatment regimens may prolong survival for elderly patients with GBM. However, further studies, particularly prospective randomized clinical trials, should be conducted to provide more definitive data on the appropriate management of elderly patients, especially for patients with MGMT promoter methylation.
Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification Feb. 14, 2022, 3:14 p.m.
Dysregulation of tyrosine kinase receptor (RTK) signaling pathways play important roles in glioblastoma (GBM). However, therapies targeting these signaling pathways have not been successful, partially because of drug resistance. Increasing evidence suggests that tumor heterogeneity, more specifically, GBM-associated stem and endothelial cell heterogeneity, may contribute to drug resistance. In this perspective article, we introduce a high-throughput, quantitative approach to profile plasma membrane RTKs on single cells. First, we review the roles of RTKs in cancer. Then, we discuss the sources of cell heterogeneity in GBM, providing context to the key cells directing resistance to drugs. Finally, we present our provisionally patented qFlow cytometry approach, and report results of a “proof of concept” patient-derived xenograft GBM study.
New Approaches to Glioblastoma Feb. 12, 2022, 8:47 a.m.
Faced with unique immunobiology and marked heterogeneity, treatment strategies for glioblastoma require therapeutic approaches that diverge from conventional oncological strategies. The selection and prioritization of targeted and immunotherapeutic strategies will need to carefully consider these features and companion biomarkers developed alongside treatment strategies to identify the appropriate patient populations. Novel clinical trial strategies that interrogate the tumor microenvironment for drug penetration and target engagement will inform go/no-go later-stage clinical studies. Innovative trial designs and analyses are needed to move effective agents toward regulatory approvals more rapidly.
Cáncer: Dan con la llave que puede frenar el glioblastoma, el tumor cerebral más agresivo Feb. 12, 2022, 8:40 a.m.
Conocer las claves del cáncer se convierte en la herramienta más eficaz para lograr hacer frente a esta enfermedad. Y ahora un estudio con participación española, coordinado por el Instituto Biodonostia, ha logrado dar un importante paso hacia delante con un nuevo hallazgo científico en Oncología. En concreto, los investigadores han logrado identificar una capacidad desconocida en las células madre malignas del glioblastoma, el tumor cerebral más frecuente y agresivo, para servirse de un mecanismo de reciclado, limpieza y regeneración celular, y eludir así los tratamientos de quimioterapia, tal y como se ha publicado hoy en la prestigiosa revista científica «Cancer Research», perteneciente al grupo de la American Association for Cancer Research.
Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints Feb. 12, 2022, 8:38 a.m.
Glioblastoma multiforme is the most lethal intrinsic brain tumor. Even with the existing treatment regimen of surgery, radiation, and chemotherapy, the median survival time is only 15–23 months. The invasive nature of this tumor makes its complete removal very difficult, leading to a high recurrence rate of over 90%. Drug delivery to glioblastoma is challenging because of the molecular and cellular heterogeneity of the tumor, its infiltrative nature, and the blood–brain barrier.